The CHDI Fifth Annual HD Therapeutics Conference, held in Palm Springs, CA, 
included topics covering new therapeutic developments in the field of 
Huntington's disease (HD). This conference report highlights presentations on 
biomarkers in HD; emerging topics in drug targeting, such as the lysosomal 
degradation pathway and target prediction by network-based modeling; 
understanding phenotype and neuronal circuit dysfunction in animal models; 
regulation of huntingtin protein expression and function; RNAi and antisense 
technology to deplete the mutant huntingtin protein; and small-molecule drugs 
that are progressing quickly through the clinic. Investigational drugs discussed 
include ALN-HTT (Alnylam Pharmaceuticals Inc/Medtronic Inc), EPI-743 (Edison 
Pharmaceuticals Inc), LNK-754 (Link Medicine Corp) and pridopidine (NeuroSearch 
A/S).